1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cervical Cancer Version 1.;Anon,2018
2. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort;Chow;J. Clin. Oncol.,2016
3. Immunotherapy of ovarian cancer: the role of checkpoint inhibitors;De Felice;J. Immunol. Res.,2015
4. New approaches in glioblastoma multiforme: the potential role of immune-check point inhibitors;De Felice;Curr. Cancer Drug Targets,2017
5. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N. Engl. J. Med.,2016